First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors

This trial is open to adults aged 18 and over who have been diagnosed with an advanced solid tumour. An advanced tumour means the cancer has either grown locally into nearby tissues or spread to other areas of the body, and standard treatments may no longer be working.

To be eligible, participants generally need to be well enough to carry out day-to-day activities and attend regular hospital visits. Doctors will check each person's general health, including how well their heart, liver, and kidneys are functioning.

People may not be able to join if they have certain serious medical conditions, uncontrolled infections, or if they are currently receiving other cancer treatments that could interfere with the study medicines. A doctor will carefully review each person's medical history to see if the trial is a safe choice for them.

Taking part in this study involves close medical supervision at a specialist hospital. Participants will receive ATX-898 either on its own or together with another cancer medicine, taken as tablets or given as injections. Before starting, you will have baseline health checks, including blood tests, physical exams, heart traces (ECGs), and imaging scans such as CT or MRI scans. During the trial, you will need to attend frequent clinic visits so the medical team can monitor your vital signs, check for side effects, and see how your body breaks down the medicine. Scans will be repeated at regular intervals to see how the tumour responds. Treatment can continue for as long as it helps you and does not cause severe side effects, followed by regular check-ins once treatment ends.